原标题：9月13日收评：上证指数微涨0.05% 两市成交7713亿今天（2022年09月13日）沪深A股两市，上证指数小幅高开，报收3263.80点，涨幅1.74点，微涨0.05%；深圳成指小幅高开，报收11923.47点，涨幅45.68点，小涨0.39%；创业板指高开，报收2550.62点，涨幅2.41点，微涨0.10%。         Francesco Faiola
Editor's Note:
Ahead of the opening of the 2026 World AI Conference and High-Level Meeting on Global AI Governance, Chinese AI start-up Moonshot AI released its Kimi K3 large language model. As the world's largest open-source model by parameter count to date, this launch marks a significant step forward in the development of China's artificial intelligence models.
From the C919 airliner soaring into the skies to Unitree's humanoid robots stealing the show; from DeepSeek pushing the AI frontier to Moonshot AI's landmark unveiling of Kimi K3 - China's wave of homegrown innovations has dominated global headlines in recent years, delivering a steady stream of breakthroughs.
At a meeting in Beijing that brought together the national science and technology award conference, the general assemblies of the members of the Chinese Academy of Sciences (CAS) and the Chinese Academy of Engineering (CAE), and the 11th national congress of the China Association for Science and Technology in July, Chinese President Xi Jinping, also general secretary of the Communist Party of China (CPC) Central Committee and chairman of the Central Military Commission, stressed that the 15th Five-Year Plan period (2026-2030) is a critical phase for tackling tough challenges in building up the country's strength in science and technology.
"We must seize the historic opportunity, rise to the challenges of the times, accelerate efforts to achieve high-level self-reliance and strength in science and technology, and make steady progress toward the 2035 goal of becoming a leading country in science and technology," he said.
In the article "Strive for Greater Strength and Self-Reliance in Science and Technology" included in the fourth volume of Xi Jinping: The Governance of China, Xi pointed out, "Through years of endeavor, our country's overall strength in science and technology has improved substantially. We therefore have a solid foundation, and are fully confident in our ability to seize the opportunities offered by the new revolution in science, technology and industry to achieve greater results." The article also mentioned that "We should participate to the full in global science and technology governance, contribute Chinese wisdom, and shape a philosophy of technology for good purposes, so that science and technology better serve human wellbeing, and enable China's science and technology industry to contribute more to building a global community of shared future."
In the 27th installment of the special series "Decoding the Book Xi Jinping: The Governance of China," the Global Times, along with the People's Daily Overseas Edition, continues to invite Chinese and foreign scholars, translators of Xi's works, practitioners with firsthand experience, and international readers to focus on the theme of striving for greater strength and self-reliance in science and technology. Together, they share views on China's tech growth, governance principles, and global cooperation in science and technology.
In the 27th article of the "Readers' Reflections" column, Global Times (GT) talked to Francesco Faiola (Faiola), an Italian professor at the Research Center for Eco-Environmental Sciences with Chinese Academy of Sciences and recipient of the Chinese Government Friendship Award.
GT: Chinese President Xi Jinping delivered a keynote speech at the opening ceremony of the 2026 World AI Conference and High-Level Meeting on Global AI Governance on July 17. He said that as a responsible major country, China is always committed to providing international public goods relating to AI. In the article "Boost Basic Research and Achieve Greater Strength and Self-Reliance in Science and Technology" included in the fifth volume of Xi Jinping: The Governance of China, Xi said, "It is important that we adopt a more open-minded approach to international exchange and cooperation in research to create an open, globally competitive innovation ecosystem." Amid the current complex global landscape, China remains firmly committed to keeping its doors open to international scientific collaboration. In your view, where does China's confidence in this commitment come from?
Faiola: I think China's confidence in staying open comes from a deep shift in mindset. The Chinese people, especially the scientific community, now really believe they are not inferior to Westerners. For a long time, even many people here thought top science had to happen at a Western address. When I first came, I believed that too. The US and Europe seemed like the only serious places for breakthroughs. Now that idea is changing, and moving toward China, because the evidence of leadership is everywhere: stem cell standards, artificial intelligence (AI) efficiency, green manufacturing. It's undeniable. China knows it has everything needed to attract and keep international talent. It's no longer a developing country playing catch up. It's a place that's helping set the global agenda.
That self-assurance is the bedrock of openness. When you truly believe you have unique strengths, like a huge organoid screening capability or a community of scientists who think deeply, you don't fear open doors. You want colleagues from everywhere to walk through so the science moves faster. My own lab works with European centers as equals. That parity is real. But we also know not everyone abroad gets this transformation yet. A lot of people still imagine Chinese science as just following others. That's exactly why China is pushing openness harder: funding lines for foreign principal investigators, open innovation hubs in Beijing, active participation in setting international standards. These aren't defensive moves. They're proof of a country confident enough to invite the world in, show what it can do, and create knowledge together.
On a deeper level, the confidence is also just rational. The big challenges - environmental problem, pandemic preparedness and precision medicine - are global. If China closed itself off, the data and validation its own regulators need would get weaker. So, the open door isn't charity. It's the smart recognition that scientific greatness today gets multiplied when you share it.
GT: In the article "Strive for Greater Strength and Self-Reliance in Science and Technology" included in the fourth volume of Xi Jinping: The Governance of China, Xi pointed out, "Through years of endeavor, our country's overall strength in science and technology has improved substantially. We therefore have a solid foundation, and are fully confident in our ability to seize the opportunities offered by the new revolution in science, technology and industry to achieve greater results." From the domestically built large passenger jet to DeepSeek, Unitree Robotics, and Moonshot AI's Kimi K3, China's innovation achievements have been making headlines. How do you assess China's achievements in sci-tech innovation in recent years? 

Faiola: I measure China's innovation success in a very personal way. My parents are old, living in a small Italian town. They don't speak English. They don't understand molecular biology. They can't read a scientific paper. But over the past few years, they've called me up more than once, excited, telling me about a Chinese airplane or a humanoid robot or some AI breakthrough they saw on Italy's main TV news or in the newspapers.
That tells me something deep. These aren't niche stories for tech insiders. They are real global news, landing in the living rooms of retirees who barely use a smartphone. I'm not bragging to them about China's progress. They are telling me. When achievements get that far into everyday European life, it's a sign China is doing something the world finds worth talking about.
The C919 plane, DeepSeek, Unitree Robotics - these aren't one-off hits. They prove China can now conceive, design, and build complex, original systems on its own, whether it's an airliner, an advanced AI model, or an agile robot. That takes deep integration across different fields, aerodynamics, materials, real time control, and AI.
DeepSeek's whole philosophy, doing more with less, is exactly how we created affordable organoid screening tools. And the quiet shift from rule taker to rule maker in chemical safety standards, that mirrors the C919's ambition to compete globally on certification. All this shows China is blending manufacturing, digital smarts, and biology into one force. But my real proof is what I hear from my students. They don't just apply discoveries from papers anymore. They question the assumptions behind them. That intellectual confidence, and the fact it echoes all the way back to a small Italian town, is why I'm sure China will fully seize this moment.
GT: President Xi said that AI development should not be a solo performance by a single country, but a symphony of international cooperation. Having conducted research in China for many years, you are not only a witness but also a driving force behind China-Europe scientific exchanges. Looking ahead, how can both sides deepen complementary advantages and achieve mutually beneficial empowerment to jointly address global challenges such as climate change and health? Over the next five years, which specific sectors should China-Europe science and technology collaboration prioritize?
Faiola: I grew up in Italy and now I lead a lab in Beijing while working with colleagues all over Europe. So, China-Europe teamwork isn't some abstract idea to me. It's how my week actually looks. The old cliché, European basic research plus Chinese scale and speed, is already outdated. Both sides now generate novel insights. The relationship has to become genuine two-way cocreation.
I see three practical things that would deepen it. First, we need truly joint funding: one grant, one integrated team, maybe a Max Planck group and a Chinese Academy of Sciences group, with a single scientific plan and students who genuinely rotate between the labs. Second, we need to harmonize regulations and ethics for organoid technologies. Europe has advanced thinking on governance. China has manufacturing scale and the drive to get things into clinics. If we co-develop shared quality and ethical standards for organoid testing, we basically set the global benchmark. A liver organoid made in Europe could then be used directly for a toxicity screen in China without repeating all the validation. Third, we need deliberate talent circulation, not a zero-sum competition. Joint PhD programs where a student naturally moves between continents.
The science doesn't care about borders. If we build the shared tools now, China and Europe can show the world a model where shared knowledge beats division.
GT: Recently, some Western media and think tanks are peddling "China Shock 2.0," claiming that China is achieving fast development in high-tech sectors such as renewable energy and AI and relies on foreign markets to absorb its overcapacity, thus reducing the market share of developed countries and sending more serious shock waves to the global economy compared with the era of traditional manufacture industry. What's your comment on this? In your view, does this represent a new pretext for Western protectionism, or is it an unavoidable external misunderstanding amid China's industrial upgrading?

Faiola: I'm a bench scientist, not a political analyst. I stick to what I can see and measure in my own work. So, I'm not going to guess what the media or think tanks intend. I'll just tell you what the facts show me, and from my lab, the "China Shock 2.0" story just doesn't match up.
In my field of stem cell toxicology, the world is desperate for human relevant safety tests to replace animal testing. Tens of thousands of chemicals still don't have proper hazard data. When Chinese labs turn out high throughput organoid platforms at a fraction of the old cost, that's not dumping "overcapacity" into a full market. It's filling a huge shortage. A researcher in Brazil or Kenya suddenly gets access to a toxicity screen that never existed for them before. Demand is skyrocketing, not standing still. Meeting that demand is a service, not a shock.
With AI, it's the same pattern. DeepSeek's efficiency makes it cheaper and easier for biomedical researchers around the world to use these tools. It's helping create new markets, not stealing a fixed pie. Sure, any big shift causes some dislocation. The answer to that is domestic support and transition policies, not blocking technologies that help solve planetary problems.
。两市一共成交7713.50亿元。其中，沪市成交3390.22亿元，深市成交4323.29亿元。深市中，创业板成交1291.28亿元，中小板成交613.87亿元。两市成交不足万亿，成交量温和，资金市场情绪温和。截止目前，沪深京A股涨跌个股涨(2551)、平(178)、跌(2152)，市场总体赚钱效应为52.26%。市场赚钱动能温和，做多意愿较强。

B | 两市涨停个股共47家，两市涨停家数不足50家，市场相对冷清，打板情绪低迷。热点行业分析今日涨幅居前的行业有：啤酒(3.51%)、超市连锁(3.45%)、黄金(2.55%)、航空(2.53%)、饲料(2.36%)、酒店餐饮(2.07%)、农业综合(1.91%)、汽车整车(1.76%)、红黄药酒(1.76%)、种植业(1.65%)。1、啤酒（3.51%）啤酒行业今日兰州黄河等个股涨停，重庆啤酒(4.36%)、青岛啤酒(3.50%)、惠泉啤酒(3.39%)、*ST西发(1.90%)、珠江啤酒(1.61%)等跟涨。

C | 2、超市连锁（3.45%）超市连锁行业今日人人乐、中百集团等个股涨停，华联综超(3.09%)、新 华 都(2.77%)、步 步 高(2.16%)、三江购物(1.97%)、文峰股份(1.48%)等跟涨。3、黄金（2.55%）黄金行业今日无个股涨停，赤峰黄金(5.81%)、*ST园城(4.99%)、*ST荣华(4.94%)、湖南黄金(4.68%)、银泰黄金(3.76%)等涨幅居前。4、航空（2.53%）航空行业今日立航科技等个股涨停，航亚科技(8.36%)、超卓航科(6.08%)、航发科技(4.79%)、安达维尔(4.53%)、广联航空(4.53%)等跟涨。5、饲料（2.36%）饲料行业今日无个股涨停，天邦食品(6.16%)、中牧股份(5.53%)、正虹科技(4.67%)、海大集团(3.87%)、新 希 望(3.03%)等涨幅居前。6、酒店餐饮（2.07%）酒店餐饮行业今日同庆楼等个股涨停，锦江酒店(3.16%)、全 聚 德(2.13%)、岭南控股(2.01%)、西安饮食(1.73%)、首旅酒店(1.42%)等跟涨。7、农业综合（1.91%）农业综合行业今日无个股涨停，鹏都农牧(7.19%)、傲农生物(6.14%)、新农开发(4.96%)、湘佳股份(3.98%)、牧原股份(3.62%)等涨幅居前。8、汽车整车（1.76%）汽车整车行业今日安凯客车、亚星客车等个股涨停，赛力斯(6.16%)、金龙汽车(5.30%)、ST曙光(4.94%)、江淮汽车(2.29%)、长城汽车(2.20%)等跟涨。9、红黄药酒（1.76%）红黄药酒行业今日无个股涨停，ST通葡(5.09%)、中葡股份(4.96%)、莫高股份(2.39%)、百润股份(1.88%)、会稽山(1.49%)等涨幅居前。10、种植业（1.65%）种植业行业今日无个股涨停，雪榕生物(6.17%)、华绿生物(5.23%)、众兴菌业(4.22%)、万辰生物(3.63%)、香梨股份(1.82%)等涨幅居前。热点题材概念分析今日涨幅居前的题材概念有：大豆(4.4%)、宠物经济(3.17%)、动物疫苗(2.58%)、啤酒概念(2.43%)、猪肉(2.22%)、人造肉(2.06%)、养鸡(2.03%)、大飞机(2.03%)、社区团购(2.02%)、中韩自贸区(1.82%)。1、大豆（4.4%）大豆概念今日N嘉华、祖名股份等个股涨停，先达股份(8.18%)、鹏都农牧(7.19%)、大北农(1.61%)、北大荒(1.49%)、荃银高科(1.37%)等跟涨。2、宠物经济（3.17%）宠物经济概念今日绿康生化、祖名股份、普莱柯等个股涨停，回盛生物(8.59%)、金河生物(6.10%)、海大集团(3.87%)、科前生物(3.86%)、瑞普生物(3.51%)等跟涨。3、动物疫苗（2.58%）动物疫苗概念今日普莱柯等个股涨停，金河生物(6.10%)、中牧股份(5.53%)、科前生物(3.86%)、瑞普生物(3.51%)、海利生物(3.38%)等跟涨。4、啤酒概念（2.43%）啤酒概念概念今日兰州黄河等个股涨停，重庆啤酒(4.36%)、怡 亚 通(3.92%)、青岛啤酒(3.50%)、惠泉啤酒(3.39%)、品渥食品(2.88%)等跟涨。5、猪肉（2.22%）猪肉概念今日无个股涨停，天邦食品(6.16%)、傲农生物(6.14%)、正虹科技(4.67%)、湘佳股份(3.98%)、海大集团(3.87%)等涨幅居前。6、人造肉（2.06%）人造肉概念今日祖名股份等个股涨停，山东赫达(8.14%)、雪榕生物(6.17%)、东宝生物(2.77%)、唐人神(2.48%)、美盈森(1.65%)等跟涨。7、养鸡（2.03%）养鸡概念今日无个股涨停，湘佳股份(3.98%)、华统股份(3.52%)、益生股份(3.20%)、新 希 望(3.03%)、晓鸣股份(2.99%)等涨幅居前。8、大飞机（2.03%）大飞机概念今日通达股份、立航科技、润贝航科等个股涨停，南方精工(8.46%)、航亚科技(8.36%)、炼石航空(6.76%)、楚江新材(5.01%)、航发科技(4.79%)等跟涨。9、社区团购（2.02%）社区团购概念今日祖名股份、中百集团等个股涨停，甘源食品(7.49%)、怡 亚 通(3.92%)、若羽臣(2.91%)、品渥食品(2.88%)、步 步 高(2.16%)等跟涨。10、中韩自贸区（1.82%）中韩自贸区概念今日青岛金王等个股涨停，连云港(2.49%)、锦州港(1.93%)、青岛双星(1.86%)、中创物流(1.12%)、渤海轮渡(0.70%)等跟涨。后市分析波段操作上，大盘自2022年09月05日3186.93发出买入信号以来，今日仍处于持仓状态；若今日大盘收盘跌破3239.05点，则选择减仓或清仓离场以规避风险；今日大盘收盘3263.80点仍处于3239.05点之上，仍可持仓观望。中线操作上，大盘自2022年09月06日3205.42发出买入信号以来，今日仍处于持仓状态；若今日大盘收盘跌破3227.86点，则选择减仓或清仓离场以规避风险；今日大盘收盘3263.80点仍处于3227.86点之上，仍可持仓观望。每日收盘点评仅供参考。股市有风险，入市需谨慎！返回搜狐，查看更多责任编辑：